Hodgkin Lymphoma Transplant Outcomes Show Significant Improvement

Outcomes have substantially improved over time for patients with relapsed or refractory classical Hodgkin lymphoma who underwent hematopoietic cell transplantation (HCT), according to a retrospective, registry-based cohort study. The research, published in the journal Blood, analyzed data from the Center for International Blood and Marrow Transplant Research (CIBMTR) registry, encompassing patients who received HCT between 1995 and 2019. This extensive dataset allowed researchers to track trends and identify factors contributing to improved survival and reduced complications.

The study identified a significant decrease in non-relapse mortality (NRM) over the study period. NRM, which includes deaths from treatment-related toxicity, infections, and graft-versus-host disease (GVHD), is a critical measure of HCT success. The decline in NRM is attributed to advancements in supportive care, including better infection prophylaxis and management, improved conditioning regimens, and enhanced GVHD prevention and treatment strategies. These improvements have made HCT a safer procedure, allowing more patients to benefit from its potentially curative effects.

Furthermore, the study observed an increase in overall survival (OS) and progression-free survival (PFS) for patients undergoing HCT for Hodgkin lymphoma. OS refers to the percentage of patients alive at a specific point in time after transplantation, while PFS measures the time patients live without their cancer progressing. The observed improvements in OS and PFS suggest that HCT is becoming more effective in controlling or eradicating the disease, even in cases where initial treatments have failed. This trend indicates a growing success rate for HCT as a salvage therapy for this challenging hematologic malignancy.

Researchers also noted changes in transplant practices over the two decades studied. These include a shift towards reduced-intensity conditioning (RIC) regimens, particularly in older patients or those with comorbidities, which can lower treatment-related toxicity. The increased use of unrelated donor transplants and improved HLA matching techniques also likely contributed to better outcomes by reducing the risk of graft rejection and GVHD. The study underscores the dynamic nature of HCT, with continuous innovation and refinement of techniques leading to progressively better results for patients with relapsed or refractory classical Hodgkin lymphoma.